Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Ciprocopan Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Brixton Metals Reports 97.0% Gold Recovery in Initial Metallurgical Work from the Trapper Gold Target
GoldInxs Commences Maiden Drill Program at the Fishpot Project, Testing Multiple Gold-Silver and Copper-Gold Targets
